Tim Smith

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

A new study shows that a mother's inflammatory diet before birth can have an impact on a child's wheeze trajectory.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).

This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.

The study indicated the potential of preventative drug lists (PDLs) as a strategy for those who have high deductible health plans to address both patient access and affordability of asthma care.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

These new findings may help shape both the design and the use of an educational intervention on technology-based inhaler techniques for patients with pediatric asthma.

New data on dupilumab demonstrate the drug’s potential usefulness in treating type 2 inflammation, a role central to respiratory diseases, including chronic obstructive pulmonary disease (COPD).

These findings highlight the potential of dupilumab in improving lung function among children that are shown to have uncontrolled, moderate-to-severe type 2 inflammation asthma.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.

A research letter highlighted recent findings that iREACH educational intervention training may be helpful in preventing peanut allergies.